[1]Hwang D, Wang HL. Medical contraindications to implant therapy: part II: relative contraindications. Implant Denti. 2007;16(1):13-23.
[2]Bornstein MM, Cionca N, Mombelli A. Systemic conditions and treatments as risks for implant therapy. Int J Oral Maxillofac Implants. 2009;24 Suppl:12-27.
[3]席光伟,王学玲,宫琳,等.辛伐他汀涂层内固定对大鼠骨质疏松骨折愈合晚期的影响[J].中国组织工程研究, 2013,17(51): 8827-8833.
[4]Jiang GZ, Matsumoto H, Hori M, et al. Correlation among geometric, densitometric, and mechanical properties in mandible and femur of osteoporotic rats. J Bone Miner Metab. 2008;26(2):130-137.
[5]Brennan-Calanan RM, Genco RJ, Wilding GE, et al. Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res. 2008;87(4):323-327.
[6]Chang PC, Lang NP, Giannobile WV. Evaluation of functional dynamics during osseointegration and regeneration associated with oral implants. Clin Oral Implants Res. 2010; 21(1):1-12.
[7]马俊岭,郭海英,阳晓东.骨质疏松症的流行病学概况[J].中国全科医学,2009,12(9):1744-1746.
[8]Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants. 2003;18(2):218-223.
[9]Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33): 25103-25108.
[10]Al-Bataineh MM, Gong F, Marciszyn A, et al. Regulation of the Proximal Tubule Vacuolar H+-ATPase by PKA and AMP-Activated Protein Kinase. Am J Physiol Renal Physiol. 2014;306(9):F981-995.
[11]Laitala T, Väänänen HK. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H (+)- ATPase. J Clin Invest. 1994;93(6):2311.
[12]Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nature Genet. 2000;25(3):343-346.
[13]Kartner N, Manolson MF. Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H+-ATPase as an emerging target. Expert Opin Drug Discov. 2014;9(5):505-522.
[14]Niikura K, Takano M, Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol. 2004;142(3):558-566.
[15]方忠,杨琴,李锋,等.去势法兔骨质疏松模型建立的探讨[J].中国骨质疏松杂志,2005,11(2):202-205.
[16]吴松涛,孟维艳,蔡青,等.PTH (1-34)对兔骨质疏松种植体骨结合影响的研究[J].实用口腔医学杂志, 2011,27(2):181-184.
[17]Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212(3):341-346.
[18]Price PA, June HH, Buckley JR, et al. SB 242784, a selective inhibitor of the osteoclastic V-H+-ATPase, inhibits arterial calcification in the rat. Circ Res. 2002;91(6):547-552.
[19]Nyman JKE, Väänänen HK. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform. Calcif Tissue Int. 2010;87(3):273-283.
[20]Tarakida A, Higuchi T, Mizunuma H. [Evidence of hormone replacement therapy for osteoporosis]. Clin Calcium. 2008; 18(10):1434-1441.
[21]Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Women's Health. 2008;8(1):22.
[22]侯玉东,余萍萍,韩晓鹏,等.雌激素干预吸烟骨质疏松大鼠种植体周围的骨沉积[J].中国组织工程研究,2012,16(46):8556-8560.
[23]Minsk L, Polson AM. Dental implant outcomes in postmenopausal women undergoing hormone replacement. Compend Contin Educ Dent. 1998;19(9):859-862.
[24]Wang Y, Yang X, Li X, et al. Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician- gynecologists: results of a survey. Menopause. 2014. [Epub ahead of print].
[25]Dikicier E, Karaçayl? Ü, Dikicier S, et al. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats. J Craniomaxillofac Surg. 2014. pii: S1010-5182(14)00041-9.
[26]张玉芹,邓久鹏,戚孟春,等.局部应用唑来膦酸对骨质疏松大鼠种植体骨结合的影响[J].中国老年学杂志, 2012,32(15):3227- 3229.
[27]李春艳,周延民,王林,等.阿仑膦酸钠对骨质疏松种植体骨结合影响的力学研究[J].华西口腔医学杂志,2011,29(3):328-329.
[28]Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis Expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324-333.
[29]李国宾,贾素侠,陈旻生,等.辛伐他汀对骨质疏松患者种植体周围骨的影响[J].中国实用医药,2012,7(18):49-50.
[30]Ahn SJ, Leesungbok R, Lee SW, et al. Differences in implant stability associated with various methods of preparation of the implant bed: An in vitro study. J Prosthet Dent. 2012;107(6): 366-372.
[31]蒋柳宏,景向东,闫春歌,等.仙灵骨葆对骨质疏松状态下纯钛种植体骨结合的影响[J].新中医,2008,40(4):100-101.
[32]Ustun Y, Erdogan O, Kurkcu M, et al. Effects of low-intensity pulsed ultrasound on dental implant osseointegration: a preliminary report. Eur J Dent. 2008;2:254.
[33]Danoux CB, Barbieri D, Yuan H, et al. In vitro and in vivo bioactivity assessment of a polylactic acid/hydroxyapatite composite for bone regeneration. Biomatter. 2014;4(1): e27664.
[34]张帆,陈晖,程志鹏.加速口腔种植体愈合的相关性研究现状[J]. 全科医学临床与教育,2009,7(5):503-305.
[35]Sørensen MG, Henriksen K, Neutzsky‐Wulff AV, et al. Diphyllin, a Novel and Naturally Potent V‐ATPase Inhibitor, Abrogates Acidification of the Osteoclastic Resorption Lacunae and Bone Resorption. J Bone Mineral Res. 2007; 22(10):1640-1648.
[36]Niikura K. Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats. J Periodontol. 2006;77(7):1211-1216.
[37]Kempen DHR, Lu L, Heijink A, et al. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials. 2009;30(14):2816-2825.
[38]Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005;20(9):1579-1588.
[39]Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011;9(7): 845-855.
[40]Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, et al. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev. 2009;35(8):707-713. |